The 2022 Drug Report shows that medication costs increased significantly in 2021 to more than CHF 8 billion, primarily driven by isolated new medicinal treatments at very high price points. The authorities are increasingly keeping medication prices secret.
The latest Helsana Drug Report shows that the medication costs borne by basic insurance exceeded CHF 8 billion for the first time in 2021. This development is down to isolated new medicinal therapies for treating various cancers and tumours – at very high price points. The prices of these medications are increasingly being kept confidential.
In addition, the report looks at three further topics: Are women being properly served in terms of medication with regard to possible pregnancy? What do the general public think about the issue of polypharmacy? And not least: new migraine prophylaxis is being put to the test.
The Helsana Drug Report is the only one of its kind in Switzerland. The report – compiled in cooperation with the University Hospital Basel (USB) and the European Center of Pharmaceutical Medicine (ECPM) at the University of Basel – provides authentic insights into the supply of medicinal products in Switzerland. We also cast a critical eye on the market for medicinal products, look for anomalies and differences, and identify room for improvement.
The report is in German. The preface and summary are available in English, German and French.
We're here to help.